Teneligliptin
Generic Name: Teneligliptin (Teneligliptin Hydrobromide Hydrate)
Uses & Medical Indications
Adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus, either as monotherapy or in dual/triple combination therapy with metformin, sulfonylureas, glitazones, alpha-glucosidase inhibitors, SGLT2 inhibitors, or insulin; especially preferred in diabetic patients with comorbid mild, moderate, or severe chronic kidney disease (CKD) or diabetic nephropathy.
Type 2 Diabetes Mellitus, Diabetic Nephropathy (Diabetic Kidney Disease), Glycemic Variability
Work Mechanism & Pharmacology
Patient Overview of Work Mechanism
Teneligliptin works as an incretin enhancer. When you eat, your digestive tract produces natural gut hormones (GLP-1) that signal your pancreas to release insulin and stop releasing extra sugar into your blood. Normally, a bodily enzyme called DPP-4 quickly destroys these helpful hormones. Teneligliptin blocks DPP-4, allowing your natural gut hormones to stay active longer, naturally stabilizing your blood sugar levels after meals and throughout the day without causing weight gain or low blood sugar.
Clinical Mechanism of Action (MoA)
Teneligliptin is an orally active, highly potent, long-acting, and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor. It features a unique molecular chemical architecture ('J-shaped' structure) containing five distinct binding pharmacophores that anchor into the S1, S2, S1', S2', and extensive S2 sub-sites of the DPP-4 enzyme. This extensive binding confers exceptional enzyme-inhibitory potency and prolonged dissociation kinetics. Under normal physiology, incretin hormones—principally glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—are released from the gut in response to food and stimulate insulin secretion, but are rapidly inactivated within 1-2 minutes by circulating DPP-4 enzymes. By reversibly inhibiting DPP-4 activity (inhibiting over 80% of enzyme activity throughout 24 hours), teneligliptin elevates and preserves active, intact physiological incretin levels. Elevated GLP-1 and GIP stimulate glucose-dependent insulin secretion from pancreatic beta cells while concurrently suppressing inappropriate excess glucagon secretion from pancreatic alpha cells. This dual physiologic action reduces both fasting plasma glucose (FPG) and postprandial glucose (PPG) fluctuations with negligible risk of intrinsic hypoglycemia or weight gain. Uniquely, teneligliptin undergoes balanced dual-pathway elimination (approx. 65% hepatic clearance and 35% renal excretion), requiring no dosage adjustments across all stages of renal impairment.
Dosage & Administration Guidelines
Standard adult dose: 20 mg orally once daily taken with or without food at the same time every day. If glycemic control is insufficient after 4 to 8 weeks, the dose may be increased up to 40 mg once daily under close medical supervision.
Safety and effectiveness have not been established in pediatric patients under 18 years of age.
20 mg once daily; no dosage adjustments required based purely on age. Clinical studies demonstrate consistent efficacy and safety in elderly diabetics.
40 mg once daily.
No dosage adjustment is required in mild, moderate, severe renal impairment, or end-stage renal disease (ESRD) on hemodialysis due to balanced dual hepatic-renal elimination.
No dosage adjustment necessary in mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
Side Effects & Safety Warnings
Hypoglycemia (mainly when combined with sulfonylurea or insulin), constipation, nausea, abdominal discomfort, headache, nasopharyngitis, dizziness.
Acute pancreatitis (rare), severe arthralgia (joint pain), bullous pemphigoid (autoimmune skin blistering), slight QT prolongation at supratherapeutic doses (40-160 mg).
Hypersensitivity to teneligliptin or any excipient; severe diabetic ketoacidosis, diabetic coma, or pre-coma; severe infection or pre/post-operative surgical state requiring insulin.
Discontinue promptly if persistent, severe abdominal pain radiating to the back occurs (suspected acute pancreatitis). When added to sulfonylureas or insulin, decrease the secretagogue dose to avoid hypoglycemia. Use caution in patients with cardiac risk factors for QT prolongation.
Interactions (Drugs, Food & Alcohol)
Sulfonylureas (glimepiride, gliclazide) or Insulin: increased hypoglycemia risk; reduce sulfonylurea/insulin dose. Drugs that prolong QT interval (antiarrhythmics, macrolides, antipsychotics): exercise clinical caution with 40 mg dose. Strong CYP3A4 inhibitors (ketoconazole) or inducers (rifampicin) may slightly alter plasma concentrations.
Can be taken with or without food; food does not significantly influence drug exposure or clinical efficacy.
Excessive alcohol consumption increases the risk of hypoglycemia and must be avoided.
Pregnancy & Breastfeeding Safety
Safety in pregnant women has not been established; contraindicated during pregnancy. Insulin is recommended for managing gestational diabetes and pregnancy with pre-existing diabetes.
Excretion into human milk is unknown; avoid use while breastfeeding.
Patient Counseling & Practical Advice
Take teneligliptin once daily with or without food at the same time each morning. It helps your body release insulin only when your blood sugar is elevated. Inform your doctor if you experience intense stomach pain radiating to your back.
Take the missed dose as soon as remembered on that day. If you do not remember until the next day, skip the missed dose and resume your regular daily schedule. Do not take a double dose.
HbA1c (every 3 months), fasting and postprandial glucose, signs of pancreatitis (abdominal pain), ECG in patients with cardiovascular risk or electrolyte imbalances on 40 mg.
Frequently Asked Questions
Related Medicines in Antidiabetic (DPP-4 Inhibitor)
When to Seek Urgent Medical Attention
Signs of severe hypoglycemia (confusion, convulsions, loss of consciousness), acute pancreatitis, or sudden chest palpitations/arrhythmias.
Content for Teneligliptin was synthesized from standardized public health monographs, official pharmacopoeias, and health authorities:
- Central Drugs Standard Control Organization (CDSCO) — CDSCO Teneligliptin Clinical Approval & Monograph
- American Diabetes Association (ADA) — Standards of Medical Care in Diabetes - DPP-4 Inhibitor Section
- Indian Journal of Endocrinology and Metabolism — Teneligliptin: A Comprehensive Review of Pharmacology & Clinical Practice
The information provided on this website is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.